CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03586661
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:15.204163+00:00
Published At: 2026-03-11T00:00:00+00:00
Record Updated At: 2026-03-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Deleterious BRCA1 Gene Mutation", "Deleterious BRCA2 Gene Mutation", "Endometrial Adenocarcinoma", "High Grade Ovarian Serous Adenocarcinoma", "Platinum-Resistant Ovarian Carcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Progressive Disease", "Recurrent Endometrial Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-11"
protocolSection.identificationModule.nctId: "NCT03586661"
protocolSection.identificationModule.officialTitle: "A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.